Location: China, Shanghai
Employees: 11-50
Total raised: $68M
Founded date: 2021
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.07.2024 | Series A | $35M | - |
| 07.04.2022 | Series A | $33M | - |
Mentions in press and media 10
| Date | Title | Description |
| 25.07.2024 | Rona Therapeutics Secures $35 Million to Propel RNA Innovations** ** | ** In the fast-paced world of biotechnology, funding is the lifeblood that fuels innovation. Rona Therapeutics, a clinical-stage company based in Shanghai, has just secured a significant $35 million in Series A+ financing. This funding roun... |
| 19.07.2024 | Greater China Digest: Rona Therapeutics seals Series A+; HKIC partners with Galbot | LongRiver Investments has led the Series A+ round for Rona Therapeutics while embodied artificial intelligence (AI) startup Galbot has inked a deal with the Hong Kong Investment Corporation (HKIC). |
| 19.07.2024 | Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms | Financing led by LongRiver Investments with participation by new and existing global investment funds Rona will use proceeds to progress leading metabolic siRNA pipeline programs into global development and expand extra-hepatic delivery pla... |
| 19.07.2024 | Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms | Financing led by LongRiver Investments with participation by new and existing global investment funds Rona will use proceeds to progress leading metabolic siRNA pipeline programs into global development and expand extra-hepatic delivery pla... |
| 19.07.2024 | Rona Therapeutics: Nucleic Acid Drug R&D Company Raises $35 Million | Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and development, today announced it raised $35 million in Series A+ funding. This funding round was led by LongRiver Investments, with participati... |
| 15.05.2023 | Rona Therapeutics and Keymed Biosciences Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis | SHANGHAI, May 15, 2023 /PRNewswire/ -- Rona Therapeutics, Inc ("Rona") and Keymed Biosciences ("Keymed", HKEX: 02162), today announced a collaboration to jointly discover and develop first-in-class siRNA therapeutics for... |
| 25.07.2022 | Rona Therapeutics Announces Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfolio and Technology Platform | Rona to advance worldwide development of Sanofi siRNA portfolio targeting liver and other tissues Rona licensed Sanofi's siRNA platform to enable discovery programs in expanded therapeutic areas including neuro and muscular diseases, for wh... |
| 07.04.2022 | Rona Therapeutics Announces Completion of $33 Million Series A Financing to Advance Global Discovery and Development of RNA Therapeutics | - Funding from long-term investors to build leading delivery platform and scalable drug discovery engine to enable modular and programmable medicines - Company is harnessing the potential of RNA therapeutics to deliver medicines to liver an... |
| 07.04.2022 | Rona Therapeutics Closes $33M Series A Financing | Rona Therapeutics, a Shangai, China-based fully integrated platform company dedicated to the discovery, development and manufacturing of RNA therapeutics, closed a $33m Series A financing. Backers included Lilly Asia Ventures, CMB Internati... |
| - | Rona Therapeutics | “RONA Therapeutics” |